Wenyin Shi, MD, PhD
Editorial Board Member
Dr. Wenyin Shi have a strong interest in translational research in Central Nervous System and Genitourinary malignancies. My research focuses on incorporating novel molecular targeting agents into conventional anti-cancer therapy, especially in combination with radiation. Current research includes a variety of different new agents, such as anti-angiogenic agents, vascular disrupting agents, signal transduction pathway inhibitors, and immune modulators. These agents will be evaluated in clinical trials for the treatment of a broad spectrum of CNS and GU malignancies, with special focus on glioblastoma and prostate cancer.